Cargando…

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

The anti-tumour effects and mechanism of action of combretastatin A-4 and its prodrug, combretastatin A-4 disodium phosphate, were examined in subcutaneous and orthotopically transplanted experimental colon tumour models. Additionally, the ability of these compounds to directly interfere with endoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grosios, K, Holwell, S E, McGown, A T, Pettit, G R, Bibby, M C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362967/ https://www.ncbi.nlm.nih.gov/pubmed/10604728 http://dx.doi.org/10.1038/sj.bjc.6692174

Ejemplares similares

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro
por: Booth, C, et al.
Publicado: (1999)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Sodium Taurocholate Micelles in Fluorometrix Analysis
por: McGown, Linda B., et al.
Publicado: (1988)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Antitumor Drug Combretastatin-A4 Phosphate Aggravates the Symptoms of Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice
por: Tang, Zhengshan, et al.
Publicado: (2020)

Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
por: Beauregard, D. A., et al.
Publicado: (1998)

Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy
por: Gu, Yongwei, et al.
Publicado: (2019)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.
por: McGown, A. T., et al.
Publicado: (1998)

Pretreatment with tadalafil attenuates cardiotoxicity induced by combretastatin A4 disodium phosphate in rats
por: Nagashima, Yoshiyasu, et al.
Publicado: (2023)

Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor
por: Nkepang, Gregory, et al.
Publicado: (2014)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects
por: Jiang, Hong, et al.
Publicado: (2019)

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
por: Webley, S D, et al.
Publicado: (2001)

Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome
por: Burt, E C, et al.
Publicado: (1999)

Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours
por: Cheeseman, S L, et al.
Publicado: (2000)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

005 OP: ENTREPRENEURIALISM, ADAPTATION, AND DISCRETION AMONG NURSES IN A TRANSNATIONAL COLLABORATION IN MALAWI AND TANZANIA
por: McGown, M
Publicado: (2017)

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
por: Blackhall, F H, et al.
Publicado: (2001)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

An organometallic analogue of combretastatin A-4 and its apoptosis-inducing effects on lymphoma, leukemia and other tumor cells in vitro
por: Abodo Onambele, Liliane, et al.
Publicado: (2022)

Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy
por: Zhang, Mengen, et al.
Publicado: (2011)

Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model
por: Gao, Meng, et al.
Publicado: (2016)

Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats
por: Tochinai, Ryota, et al.
Publicado: (2018)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Novel heterozygous deletion in the HNF1β gene - adolescent with antibody negative diabetes, longstanding hyperglycaemia without ketosis, cataracts, small echogenic kidneys with a cortical cyst, pancreatic atrophy, exocrine pancreatic insufficiency and a uterine anomaly
por: Conwell, Louise S, et al.
Publicado: (2015)

Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs
por: Pradere, Ugo, et al.
Publicado: (2014)

Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography
por: Mampaey, Gitte, et al.
Publicado: (2022)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

PDEPT: polymer-directed enzyme prodrug therapy
por: Satchi, R, et al.
Publicado: (2001)

Interaction of the novel agent amphethinile with tubulin.
por: McGown, A. T., et al.
Publicado: (1989)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
por: Platel, D, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_7fhi57bd7lbt7g7snt24eu1hqj